<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02436928</url>
  </required_header>
  <id_info>
    <org_study_id>CT-MV-21</org_study_id>
    <nct_id>NCT02436928</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medigen Vaccine Biologics Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medigen Vaccine Biologics Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and immunogenicity of an inactivated cell culture&#xD;
      derived H7N9 vaccine in healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of AT-501 vaccine measured by Adverse Event</measure>
    <time_frame>1 year from the start of study enrolment</time_frame>
    <description>Phase 1&#xD;
Percentage, intensity and relationship to vaccination of solicited local and general signs and symptoms during a 7-day follow-up period after the first and second dose of administered vaccine.&#xD;
Percentage, intensity and relationship to vaccination of unsolicited local and general signs and symptoms during a 21-day follow-up period after each administered vaccine.&#xD;
Occurrence of overall adverse events and serious adverse events during the entire period of study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of AT-501 vaccine measured by HI titers</measure>
    <time_frame>1 year from the start of study enrolment</time_frame>
    <description>Phase 2&#xD;
HI titers as follows:&#xD;
Seroconversion Rate (SCR) at day 22 and 43&#xD;
Seroconversion Factor (SCF) at day 22 and day 43&#xD;
Seroprotection Rate (SPR) at day 22 and day 43</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of AT-501 vaccine measured HI and neutralizing antibody titers</measure>
    <time_frame>1 year from the start of study enrolment</time_frame>
    <description>Phase 1&#xD;
Change of antibody titers from baseline to day 22 and day 43&#xD;
Geometric Mean Titer (GMT) of both serum HI titers and neutralizing antibody titers, pre-vaccination and day 22 and day 43 post-vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of AT-501 vaccine measured by Adverse Event</measure>
    <time_frame>1 year from the start of study enrolment</time_frame>
    <description>Phase 2&#xD;
Percentage, intensity and relationship to vaccination of solicited local and general signs and symptoms during a 7-day follow-up period after the first and second dose of administered vaccine.&#xD;
Percentage, intensity and relationship to vaccination of unsolicited local and general signs and symptoms during a 21-day follow-up period after each administered vaccine.&#xD;
Occurrence of overall adverse events and serious adverse events during the entire period of study.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>H7N9 Influenza Vaccine</condition>
  <arm_group>
    <arm_group_label>AT-501 High Dose vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated H7N9 High Dose Antigen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-501 High Dose vaccine with Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated H7N9 High Dose Antigen with Adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-501 Low Dose vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated H7N9 Low Dose Antigen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-501 Low Dose vaccine with Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated H7N9 Low Dose Antigen with Adjuvant</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AT-501 High Dose vaccine</intervention_name>
    <description>Comparison of each dose of vaccine</description>
    <arm_group_label>AT-501 High Dose vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AT-501 High Dose vaccine with Adjuvant</intervention_name>
    <description>Comparison of each dose of vaccine</description>
    <arm_group_label>AT-501 High Dose vaccine with Adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AT-501 Low Dose vaccine</intervention_name>
    <description>Comparison of each dose of vaccine</description>
    <arm_group_label>AT-501 Low Dose vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AT-501 Low Dose vaccine with Adjuvant</intervention_name>
    <description>Comparison of each dose of vaccine</description>
    <arm_group_label>AT-501 Low Dose vaccine with Adjuvant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject within the age limit range, is free of obvious health problems as judged by&#xD;
             the investigator before entering the study.&#xD;
&#xD;
          2. Female subjects must be:&#xD;
&#xD;
               -  either of non-childbearing potential, or one year post-menopausal;&#xD;
&#xD;
               -  or, if of childbearing potential, must be abstinent or have used adequate&#xD;
                  contraceptive precautions for 30 days prior to receiving the study vaccination,&#xD;
                  have a negative pregnancy test and must agree to continue such precautions for&#xD;
                  two months after completion of the vaccination series.&#xD;
&#xD;
          3. Subject is willing and able to comply with all required study visits and follow-up&#xD;
             required by this protocol.&#xD;
&#xD;
          4. Subject must provide written informed consent or the Subjects' legal representative&#xD;
             must understand and consent to the procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with previous known or potential exposure to avian influenza virus H7N9 HA&#xD;
             antigen and any other avian influenza including H5N1.&#xD;
&#xD;
          2. Subjects who have had seasonal influenza vaccine within 6 months prior to enrolment or&#xD;
             who will have seasonal influenza vaccine at any time during the study period&#xD;
&#xD;
          3. Subjects administered with any other vaccine during the period within 6 weeks before&#xD;
             the first administration of study vaccine.&#xD;
&#xD;
          4. Subjects with confirmed or suspected abnormal immune function, immunosuppressive or&#xD;
             immunodeficient condition, including human immunodeficiency virus (HIV) infection,&#xD;
             based on medical history and physical examination.&#xD;
&#xD;
          5. Subjects with a history of hypersensitivity to vaccines or a history of allergic&#xD;
             disease or reactions likely to be exacerbated by any component of the vaccine.&#xD;
&#xD;
          6. Subjects with a history of inflammatory or degenerative neurological disease .&#xD;
&#xD;
          7. Subjects receiving chronic administration of immunosuppressants or other&#xD;
             immune-modifying drugs within 6 months prior to the administration of the study&#xD;
             vaccine. Inhaled and topical steroids are allowed.&#xD;
&#xD;
          8. Known HIV, hepatitis B (HBsAg) or hepatitis C seropositivity.&#xD;
&#xD;
          9. Subjects, judged by the investigator, with any clinically significant medical illness&#xD;
             including acute pulmonary, cardiovascular, hepatic or renal functional abnormality, as&#xD;
             determined by medical history, physical examination and/or laboratory screening tests.&#xD;
&#xD;
         10. The subjects would not be suitable for the vaccination if the screening laboratory&#xD;
             tests show any of the follows&#xD;
&#xD;
               -  ALT or AST &gt; upper limit of normal range (ULN);&#xD;
&#xD;
               -  Serum creatinine &gt; upper limit of normal range (ULN);&#xD;
&#xD;
               -  Any significant laboratory abnormality as judged by the investigator&#xD;
&#xD;
         11. Subjects receiving administration of immunoglobulins and/or any blood products within&#xD;
             the 3 months preceding the administration of the study vaccine or at any time during&#xD;
             the study.&#xD;
&#xD;
         12. Subjects with acute disease at the time of enrolment.&#xD;
&#xD;
         13. Use of any investigational or non-registered product other than the study vaccine&#xD;
             within 30 days prior to the first vaccination, or planned use of the abovementioned&#xD;
             product during the entire study period.&#xD;
&#xD;
         14. Psychiatric, addictive, or any disorder, which may compromise the ability to give a&#xD;
             truly informed consent for participation of this study or adequate compliance.&#xD;
&#xD;
         15. Any clinically relevant disease and/or abnormal laboratory findings (, which, in the&#xD;
             opinion of the Investigator, may either put the patient at risk because of&#xD;
             participation in the study, or influence the results of the study, or the patient's&#xD;
             ability to participate in the study.&#xD;
&#xD;
         16. Breast feeding or pregnant women or refusal to submit to a urine test to rule out&#xD;
             pregnancy prior to enrolment and during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shan-Chwen Chang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>April 27, 2015</study_first_submitted>
  <study_first_submitted_qc>May 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>H7N9 Influenza</keyword>
  <keyword>Avian influenza A</keyword>
  <keyword>cell culture derived</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

